Literature DB >> 21356502

Treatment of skin and soft tissue infections in the elderly: A review.

Troy D Kish1, Mei H Chang, Horatio B Fung.   

Abstract

BACKGROUND: Skin and soft tissue infections (SSTIs) have become the second most common type of infection among persons residing in long-term care facilities.
OBJECTIVE: The purpose of this article was to review the latest information on SSTIs among the elderly, including age-related changes, challenges, and treatment strategies in the era of emerging bacterial resistance.
METHODS: Relevant information was identified through a search of MEDLINE (1970-April 2010), International Pharmaceutical Abstracts (1970-April 2010), and Google Scholar using the terms skin and soft tissue infection, skin and skin structure infection, cellulitis, treatment guidelines, and elderly. Additional publications were found by searching the reference lists of the identified articles. Trials published since 1970 were selected for this review if they prospectively evaluated mostly adults (≥18 years of age), included >50 patients, and reported diagnostic criteria as well as clinical outcomes in patients treated for simple or complicated SSTIs.
RESULTS: Fifty-eight of 664 identified studies were selected and included in this review. A search of the literature did not identify any prospective clinical trials that were conducted exclusively in the elderly. Information on the treatment of SSTIs in the elderly was based solely on clinical studies that were conducted in adults in general. As recommended by the Infectious Diseases Society of America (IDSA) 2008 update, SSTIs should be suspected in elderly patients who have skin lesions and present with a decline in functional status, with or without fever. Patients who present with symptoms of systemic toxicity should be hospitalized for further evaluation. Current challenges in the management of SSTIs include the rapid emergence of community-acquired, methicillin-resistant Staphylococcus aureus (CA-MRSA), the emergence of macrolide-resistant streptococci within the past decade, and the lack of a reliable algorithm to differentiate potentially life-threatening SSTIs that require aggressive interventions and prompt hospitalization from those that can be managed in an outpatient setting. S aureus was the most common cause of SSTIs, being isolated in 42.8% (5015/11,723) of wounds, followed by streptococci. Common SSTIs in the elderly such as shingles, diabetic foot infections, infected pressure ulcers, and scabies, and their treatment were also discussed. Based on reviews of published trials, treatment of simple SSTIs generally consisted of administration of agents with activity against S aureus and Streptococcus species such as a penicillinase-resistant β-lactam, a first-generation cephalosporin, or clindamycin. Broadening of the antimicrobial spectrum to include gram-negative and anaerobic organisms should be implemented for complicated SSTIs such as diabetic foot infections and infected pressure ulcers. Local rates of MRSA, CA-MRSA, and macrolide-resistant streptococci should be considered when selecting empiric therapy.
CONCLUSIONS: A search of the literature did not identify any prospective clinical trials on the treatment of SSTIs in the elderly; therefore, it is recommended to follow treatment based on the current IDSA guidelines. More research and publications are needed to establish proper selection of antimicrobial agents, treatment strategies, and duration of therapy of SSTIs in the elderly population.
Copyright © 2010. Published by EM Inc USA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21356502     DOI: 10.1016/S1543-5946(10)80002-9

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  8 in total

Review 1.  Antimicrobial peptides and wound healing: biological and therapeutic considerations.

Authors:  Maria Luisa Mangoni; Alison M McDermott; Michael Zasloff
Journal:  Exp Dermatol       Date:  2016-02-10       Impact factor: 3.960

2.  Application of orange essential oil as an antistaphylococcal agent in a dressing model.

Authors:  Arunachalam Muthaiyan; Debabrata Biswas; Philip G Crandall; Brian J Wilkinson; Steven C Ricke
Journal:  BMC Complement Altern Med       Date:  2012-08-16       Impact factor: 3.659

Review 3.  A Proposed New Classification of Skin and Soft Tissue Infections Modeled on the Subset of Diabetic Foot Infection.

Authors:  Benjamin A Lipsky; Michael H Silverman; Warren S Joseph
Journal:  Open Forum Infect Dis       Date:  2016-12-07       Impact factor: 3.835

4.  Skin and soft tissue infections and current antimicrobial prescribing practices in Australian aged care residents.

Authors:  N J Bennett; N Imam; R J Ingram; R S James; K L Buising; A L Bull; C S Chen; K A Thursky; L J Worth
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Paraspinal Necrotizing Fasciitis Associated with Pressure Injury: An Unusual Case Report.

Authors:  Min Ji Kim; Kyung Min Yang; Hyoseob Lim
Journal:  Adv Skin Wound Care       Date:  2022-04-01       Impact factor: 2.347

6.  Incidence and predictors of hospitalization for bacterial infection in community-based patients with type 2 diabetes: the fremantle diabetes study.

Authors:  Emma J Hamilton; Natalie Martin; Ashley Makepeace; Brett A Sillars; Wendy A Davis; Timothy M E Davis
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

7.  Nasal colonization with methicillin-resistant Staphylococcus aureus among elderly living in nursing homes in Brazil: risk factors and molecular epidemiology.

Authors:  Monica da Silveira; Maria de Lourdes Ribeiro de Souza da Cunha; Camila Sena Martins de Souza; Adriana Aparecida Feltrin Correa; Carlos Magno Castelo Branco Fortaleza
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-05-04       Impact factor: 3.944

8.  Cellulitis in older people over 75 years - are there differences?

Authors:  Manoj Kumar; Vincent Jiu Jong Ngian; Clarence Yeong; Caitlin Keighley; Huong Van Nguyen; Bin Soo Ong
Journal:  Ann Med Surg (Lond)       Date:  2019-11-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.